Supplementary information
NSCLC, death, tumor
TUMOR, SQUAMOUS CELL CARCINOMA, NSCLC, REGRESSION, LARGE CELL CARCINOMA, COMPLICATIONS

Supplementary Figs. 1–7.Reporting SummaryTumor molecular alterations in both treatment arms. Splice, an alteration of genomic DNA adjacent to the intron/exon splice border, which could have an effect on RNA splicing, has been identified. *Molecular tests performed at outside institution.Pathologic responses in the ITT population in both treatment arms. Two Ipi+Nivo+CT patients were not resected due to death from SARS-CoV-2 infection-related complications (non-treatment related) in one patient and complexity of surgical resection and its associated risks in the second patient. *MPR rate was obtained from a UMVUE. VT, viable tumor; NE, not evaluable.Pathologic responses in all resected patients in both treatment arms. VT, viable tumor.Univariate logistic regression model to assess the association between clinical characteristics and MPR in combined treatment arms. OR, odds ratio; NOS, not otherwise specified; Squamous, squamous cell carcinoma. Non-squamous includes adenocarcinoma, carcinoma with neuroendocrine features, NOS NSCLC, sarcomatoid carcinoma and large cell carcinoma.Pathologic responses in the ITT population without known tumor TRAEs in both treatment arms. eGFR, estimated glomerular filtration rate; BUN, blood urea nitrogen.SAEs by grade in both treatment arms. *One patient died of SARS-CoV-2 infection-related complications (non-treatment related).Neoadjuvant treatment, pathologic response attributes and molecular alterations of patients with scRNA-seq of treated tumor and uninvolved (normal) lung tissues.Immune gene signature scores by NanoString in Immune gene signature scores by NanoString in Immune gene signature scores by NanoString in Information on flow cytometry antibody panels.Processed data and annotations.